167 related articles for article (PubMed ID: 27021608)
1. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
[TBL] [Abstract][Full Text] [Related]
2. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
Seino Y; Sasaki T; Fukatsu A; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1219-30. PubMed ID: 24597840
[TBL] [Abstract][Full Text] [Related]
4. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1231-44. PubMed ID: 24673496
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1245-55. PubMed ID: 24708292
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
[TBL] [Abstract][Full Text] [Related]
8. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Seino Y; Kaku K; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Endocr J; 2015; 62(7):593-603. PubMed ID: 25971406
[TBL] [Abstract][Full Text] [Related]
9. Luseogliflozin for the treatment of type 2 diabetes.
Seino Y
Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Sasaki T; Sugawara M; Fukuda M
J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
[TBL] [Abstract][Full Text] [Related]
12. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
Chino Y; Kuwabara M; Hisatome I
J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
[TBL] [Abstract][Full Text] [Related]
13. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Yabe D; Iwasaki M; Kuwata H; Haraguchi T; Hamamoto Y; Kurose T; Sumita K; Yamazato H; Kanada S; Seino Y
Diabetes Obes Metab; 2017 May; 19(5):739-743. PubMed ID: 27990776
[TBL] [Abstract][Full Text] [Related]
15. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
Samukawa Y; Omiya H; Watase H; Nozaki K; Sakai S; Nishimura R
Adv Ther; 2016 Jul; 33(7):1215-30. PubMed ID: 27255763
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H
Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
[TBL] [Abstract][Full Text] [Related]
18. Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.
Kario K; Okada K; Murata M; Suzuki D; Yamagiwa K; Abe Y; Usui I; Tsuchiya N; Iwashita C; Harada N; Okawara Y; Ishibashi S; Hoshide S
J Clin Hypertens (Greenwich); 2020 Sep; 22(9):1585-1593. PubMed ID: 32810338
[TBL] [Abstract][Full Text] [Related]
19. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
Bouchi R; Terashima M; Sasahara Y; Asakawa M; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
Cardiovasc Diabetol; 2017 Mar; 16(1):32. PubMed ID: 28253918
[TBL] [Abstract][Full Text] [Related]
20. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
Trials; 2020 May; 21(1):379. PubMed ID: 32370806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
